Financial analysts and institutional research firms tracking Immunic, Inc. (IMUX) have established consensus twelve-month price targets that reflect optimistic projections following recent corporate financings and pipeline advancements. Average price forecasts formulated by Wall Street professionals hover around the $47.00 range, with individual estimates varying depending on clinical trial milestones for its lead oral immunology candidate and assumptions regarding future commercialization potential. These targets are continuously revised by equity researchers in response to regulatory updates, cash runway disclosures, and broader biotechnology sector sentiment.